Shockwave Medical, Inc. (NASDAQ:SWAV – Get Free Report) Director Frank T. Watkins sold 2,000 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $231.76, for a total value of $463,520.00. Following the completion of the sale, the director now owns 4,532 shares in the company, valued at approximately $1,050,336.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shockwave Medical Price Performance
Shares of NASDAQ SWAV opened at $233.71 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 13.19 and a current ratio of 14.43. The company has a market cap of $8.62 billion, a PE ratio of 36.40, a P/E/G ratio of 10.15 and a beta of 0.88. The business has a 50-day simple moving average of $205.15 and a two-hundred day simple moving average of $207.30. Shockwave Medical, Inc. has a fifty-two week low of $157.00 and a fifty-two week high of $315.95.
Institutional Investors Weigh In On Shockwave Medical
Institutional investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC boosted its holdings in Shockwave Medical by 64.8% in the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Shockwave Medical by 297.4% in the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Shockwave Medical in the fourth quarter worth about $34,000. Nemes Rush Group LLC purchased a new position in shares of Shockwave Medical in the second quarter worth about $39,000. Finally, Quest Partners LLC purchased a new position in shares of Shockwave Medical in the fourth quarter worth about $41,000. Institutional investors and hedge funds own 87.35% of the company’s stock.
Analyst Ratings Changes
Shockwave Medical Company Profile
ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.
- Five stocks we like better than Shockwave Medical
- What Is Dividend Yield and How Do You Calculate It?
- Cloudflare results spark analysts reset: 25% upside ahead
- How to Invest in Artificial Intelligence
- Beyond Nvidia: The hidden stars with 200% earnings growth
- Growth Stocks: What They Are, Examples and How to Invest
- 3 large caps with RSIs that scream ‘oversold’
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.